



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN : L74899DL1978PLC009181

JPL/SEC/RESU-NOT1

Date : May 29th, 2015

The National Stock Exchange of India Limited
Kind Attn. Mr. Hari K. - Vice President
Exchange Plaza, Bandra-Kurla Complex
Bandra E), Mumbai - 400 051.
FAX 022-26598237-38

The Bombay Stock Exchange Limited
Pherozebhoj Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
FAX 022-22723121, 22722037, 22723719, 22722041

**SUB: AUDITED FINANCIAL RESULTS FOR QUARTER/YEAR ENDED 31.03.2015
& AUDITOR REPORT ON FINANCIAL RESULTS/CORPORATE GOVERNANCE.**

Dear Sir,

In terms of Clause 41 of the listing agreement we are sending herewith audited financial results for the quarter/year ended 31st March, 2015 and Auditor's Report on Financial Results/Corporate Governance..

Thanking you.

Yours faithfully,
for **JAGSONPAL PHARMACEUTICALS LIMITED**


R K KAPOOR
COMPLIANCE OFFICER CUM COMPANY SECRETARY

Encl. : As above.

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953
Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand
CIN No. L74899DL1978PLC009181



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)


Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181

JAGSONPAL PHARMACEUTICALS LIMITED

Audited Financial Results for the Quarter ended 31.03.2015

						Rs. in lacs
PART-I						
Particulars	3 months ended 31.03.2015 Audited	3 months ended 31.12.2014 Unaudited	3 months ended 31.03.2014 Audited	12 Months ended 31.03.2015 Audited	12 Months Ended 31.03.2014 Audited	
1 Income from operations						
a Net sales/Income from Operations (Net of excise duty)	3884.86	3242.86	3128.08	13815.09	14385.09	
b Other Operating Income						
Total Income from operations (net)	3884.86	3242.86	3128.08	13815.09	14385.09	
2 Expenses						
a Cost of materials consumed	1960.65	1567.32	1047.14	6383.36	5461.64	
b Purchases of stock-in-trade	42.59	50.18	565.48	649.48	1294.90	
c. Changes in inventories of finished goods, work	278.47	-48.08	-939.18	-164.55	-285.94	
d. Employee benefits expenses	816.96	744.79	1022.02	3211.33	3783.43	
e. Depreciation and amortisation expense	56.03	71.76	68.51	270.69	282.54	
f. Other expenses	636.83	742.01	1061.74	2862.86	3063.27	
Total expenses	3791.53	3127.98	2825.71	13213.17	13599.84	
3 Profit from Operations before Other Income, Finance Cost and Exceptional items (1-2)	93.33	114.88	302.37	601.92	785.25	
4 Other Income	5.55	0.41	6.07	11.10	6.07	
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	98.88	115.29	308.44	613.02	791.32	
6 Finance Cost	105.69	112.01	183.16	445.85	538.19	
7 Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	-6.81	3.28	125.28	167.17	253.13	
8 Exceptional Items						
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	-6.81	3.28	125.28	167.17	253.13	
10 Tax expense	-13.60	0.66	3.08	50.06	41.06	
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	6.79	2.62	122.20	117.11	212.07	
12 Extraordinary Items (net of tax expense Rs. lacs)						
13 Net Profit(+)/Loss(-) for the period(11-12)	6.79	2.62	122.20	117.11	212.07	
14 Share of profit/(Loss) of associates						
15 Minority interest						
16 Net Profit/(Loss) after taxes, minority interest	6.79	2.62	122.20	117.11	212.07	
17 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90	
18 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr				7448.74	7298.31	
19.i Earnings Per Share (before extraordinary items)						
a. Basic (Rs.)	0.03	0.01	0.47	0.45	0.81	
b. Diluted (Rs.)	0.03	0.01	0.47	0.45	0.81	
19.ii Earnings Per Share (after extraordinary items)						
a. Basic (Rs.)	0.03	0.01	0.47	0.45	0.81	
b. Diluted (Rs.)	0.03	0.01	0.47	0.45	0.81	



Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953
 Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector 5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

CIN No. L74899DL1978PLC009181



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

PART-II

A PARTICULARS OF SHAREHOLDING

1	Public Shareholding					
	- Number of shares	8962360	8962360	8962360	8962360	8962360
	- Percentage of Shareholding	30.83%	30.83%	34.21%	30.83%	34.21%
2	Promoter and promoter group shareholding					
A	Pledged / encumbered					
	- Number of shares					
	- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)					
	- Percentage of shares (as a % of the total share capital of the Company)					
B	Non - encumbered					
	- Number of shares	18121320	18121320	17235640	18121320	17235640
	- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	69.17%	69.17%	65.79%	69.17%	65.79%

B INVESTOR COMPLAINTS

Pending at the beginning of the quarter	0	0	0
Received during the quarter	44	23	40
Disposed of during the quarter	44	23	40
Remaining unresolved at the end of the	0	0	0

Notes

1. The Audited Financial Results for the Quarter ended 31.03.2015 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 29.05.2015
2. The figures for the quarter ended 31st March, 2015 represents the derived figures between the audited figures in respect of the year ended 31st March, 2015 and the unaudited published period to date figures upto 31st December, 2014 being the date of the end of the third quarter of the current year, which was subjected to a limited review.
3. In accordance with the companies Act, 2013 the company has revised the useful life of its fixed assets to comply with the useful life as mentioned under Schedule II of Companies Act, 2013. Based on transitional provision, given in Schedule II to the companies Act, 2013, the carrying value of assets whose useful lives are already exhausted amounting to Rs 385.76 lacs (net of deferred tax of Rs 64.76 lacs) has been adjusted with the opening balance of Reserve. Had there been no change in useful lives of fixed assets, the charge to the statement of profit and loss would have been lower by Rs 19.62 Lacs.
4. The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
5. The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
6. Previous year figures have been regrouped / rearranged wherever necessary.
7. The Board has recommended today, a final dividend of Rs 0.10 per share(2%) subject to approval of the shareholders at the ensuing Annual General Meeting.

By Order of the Board

For Jagsonpal Pharmaceuticals Limited



Rajpal Singh Kochhar
Managing Director
DIN No 00059492

Place : New Delhi
Date : 29.05.2015

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953
Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

CIN No. L74899DLI978PLC009181

Statement of Assets and Liabilities

Rs. In lacs

As at
31.03.2015

As at
31.03.2014

ASSETS

1

Non-current assets

5193.03

5872.74

(a) Fixed Assets

(b) Goodwill

3.00

0.05

(c) Non-current investments

0.00

0.00

(d) Deferred tax assets (net)

646.62

618.52

(e) Long term loans and advance

0.00

0.00

(f) Other non-current assets

5842.70

6494.31

Sub-total - Non-current assets

2

Current assets

(a) Current investments

3306.20

3058.92

(b) Inventories

4488.87

4522.09

(c) Trade receivables

1501.61

1260.42

(d) Cash and Cash equivalents

282.62

289.98

(e) Short term loans and advance

0.00

0.00

(f) Other current assets

9579.30

9131.41

Sub-Total - Current assets

15422.00

15625.72

TOTAL - ASSETS

EQUITY AND LIABILITIES

A

Shareholders' funds

(a) Share Capital

1309.90

1309.90

(b) Reserves and surplus

8232.66

8548.97

Sub-total - Shareholders' funds

9542.56

9858.87

Share application money pending allotment

0.00

0.00

Minority interest

0.00

0.00

Non-current liabilities

(a) Long term borrowings

360.26

408.39

(b) Deferred tax liabilities (net)

0.00

0.00

(c) Other long term liabilities

0.00

0.00

(d) Long term provisions

360.26

408.39

Sub-total - Non-current liabilities

3931.05

3595.76

Current liabilities

(a) Short term borrowing

786.89

508.45

(b) Trade payables

624.45

548.10

(c) Other current liabilities

176.79

706.15

(d) Short term provisions

5519.18

5358.46

Sub-Total - Current liabilities

15422.00

15625.72

TOTAL - EQUITY AND LIABILITIES

Director

For Jagsonpal Pharmaceuticals Limited

AUDITORS' REPORT ON CORPORATE GOVERNANCE

To the members of Jagsonpal Pharmaceuticals Limited

We have examined the compliance of conditions of Corporate Governance by Jagsonpal Pharmaceuticals Limited for the year ended on 31st March, 2015 as stipulated in Clause 49 of the Listing Agreement of the said Company with the Stock Exchanges.

The compliance of conditions of Corporate Governance is the responsibility of the management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an Audit nor an expression of opinion on the financial statement of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied in all material aspect with the conditions of Corporate Governance as stipulated by the above mentioned Listing Agreement.

We state that no investor grievances are pending for a period exceeding one month against the Company as per the records maintained by the Company and presented to the Investors' Grievances Committee.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Place: New Delhi

Date: 29th May, 2015



For P.P. Thukral & Company
Chartered Accountants
FRN No 000632 N


Suresh Sethi
Partner
M.No. 89318